- Home
- CMBM vs GOVX Comparison
CMBM vs GOVX Comparison
Compare CMBM & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMBM
- GOVX
- Stock Information
- Founded
- CMBM 2011
- GOVX 2001
- Country
- CMBM United States
- GOVX United States
- Employees
- CMBM N/A
- GOVX N/A
- Industry
- CMBM Radio And Television Broadcasting And Communications Equipment
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- CMBM Technology
- GOVX Health Care
- Exchange
- CMBM Nasdaq
- GOVX Nasdaq
- Market Cap
- CMBM 26.5M
- GOVX 23.8M
- IPO Year
- CMBM 2019
- GOVX N/A
- Fundamental
- Price
- CMBM $0.70
- GOVX $2.26
- Analyst Decision
- CMBM Strong Buy
- GOVX Strong Buy
- Analyst Count
- CMBM 3
- GOVX 5
- Target Price
- CMBM $5.50
- GOVX $14.20
- AVG Volume (30 Days)
- CMBM 144.6K
- GOVX 715.7K
- Earning Date
- CMBM 11-07-2024
- GOVX 11-12-2024
- Dividend Yield
- CMBM N/A
- GOVX N/A
- EPS Growth
- CMBM N/A
- GOVX N/A
- EPS
- CMBM N/A
- GOVX N/A
- Revenue
- CMBM $172,215,000.00
- GOVX $3,090,161.00
- Revenue This Year
- CMBM N/A
- GOVX N/A
- Revenue Next Year
- CMBM $16.49
- GOVX $150.51
- P/E Ratio
- CMBM N/A
- GOVX N/A
- Revenue Growth
- CMBM N/A
- GOVX N/A
- 52 Week Low
- CMBM $0.66
- GOVX $1.09
- 52 Week High
- CMBM $6.50
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- CMBM 26.27
- GOVX 44.80
- Support Level
- CMBM $0.66
- GOVX $2.17
- Resistance Level
- CMBM $1.25
- GOVX $2.50
- Average True Range (ATR)
- CMBM 0.11
- GOVX 0.17
- MACD
- CMBM -0.04
- GOVX -0.04
- Stochastic Oscillator
- CMBM 6.79
- GOVX 18.33
About CMBM Cambium Networks Corporation
Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.